Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.
Abstract: 2,5-dihydroxyterephthalic acid is produced in high yields and high purity from 2,5-dihaloterephthalic acid by contact with a copper source and a ligand that coordinates to copper under basic conditions.
Abstract: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.
Type:
Grant
Filed:
October 15, 2004
Date of Patent:
April 8, 2008
Assignees:
The University of North Carolina at Chapel Hill, The University of Rochester Medical Center, Androscience Corporation
Inventors:
Kuo-Hsiung Lee, Li Lin, Charles C-Y Shih, Ching-Yuan Su, Junko Ishida, Hironori Ohtsu, Hui-Kang Wang, Hideji Itokawa, Chawnshang Chang
Abstract: A process for purifying a phenol derivative selected from alkylphenols having a number average molecular weight of from 200 to 4 000 and Mannich adducts thereof is described, in which the phenol derivative is brought into intimate contact with an extracting agent having a polarity ET(30) of from 57 to 38 kcal/mol, a phase containing the phenol derivative and an extracting agent phase are allowed to separate from one another and the extracting agent phase is removed.
Type:
Grant
Filed:
April 22, 2002
Date of Patent:
April 8, 2008
Assignee:
BASF Aktiengesellschaft
Inventors:
Arno Lange, Hans Peter Rath, Marc Walter
Abstract: Disclosed is an optimized process and apparatus for more efficiently and economically carrying out the liquid-phase oxidation of an oxidizable compound. Such liquid-phase oxidation is carried out in a bubble column reactor that provides for a highly efficient reaction at relatively low temperatures. When the oxidized compound is para-xylene and the product from the oxidation reaction is crude terephthalic acid (CTA), such CTA product can be purified and separated by more economical techniques than could be employed if the CTA were formed by a conventional high-temperature oxidation process.
Type:
Grant
Filed:
March 1, 2006
Date of Patent:
April 8, 2008
Assignee:
Eastman Chemical Company
Inventors:
Alan George Wonders, Thomas Earl Woodruff, Ronald Buford Sheppard, Wayne Scott Strasser
Abstract: A process for making terpene esters is disclosed. Reaction of a terpene alcohol with acetic anhydride in the presence of a high-boiling amine provides a terpene ester. Acetic acid, which is distilled from the reaction mixture as it forms can be recovered. The terpene ester is distilled from the high-boiling amine to provide a product that is substantially free of nitrogen-containing impurities. The reaction mixture can be reused for subsequent acylations. The simple, economical process gives high-quality terpene esters while avoiding waste-disposal issues of other common acylation procedures.
Abstract: Novel benzoquinone-derived compounds and polymorphs, prodrugs, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of such compounds, polymorphs, prodrugs and isomers are provided. Process for preparation of compounds of the invention and pharmaceutical compositions containing such compounds and their use for reducing or inhibiting activity of lipase gene family for treatment, amelioration or prevention of lipase gene family mediated diseases and conditions including overweight, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, diabetes, atherosclerosis, other cardiovascular diseases, metabolic syndromes, and metabolic disorders are provided. Methods of use of the compounds for skin care, hair care and cosmetics are provided.
Abstract: A sulfide chain-bearing organosilicon compound having the average compositional formula: (R1O)(3-p)(R2)pSi—R3—S—(R4—Sm)q—R4—S—R3—Si(OR1)(3-p)(R2)p is prepared at low costs and in high yields by reacting a halogen-terminated organosilicon compound having the formula: (R1O)(3-p)(R2)pSi—R3—S—R4—X, and optionally a halide having the formula: X—R4—X and/or sulfur with an aqueous solution or dispersion of a polysulfide M2Sn or hydrate thereof in the presence of a phase transfer catalyst. R1 and R2 are monovalent C1-4 hydrocarbon groups, R3 and R4 are divalent C1-10 hydrocarbon groups, m has an average value of 2-6, n has an average value of 2-6, p is 0, 1 or 2, q is 1, 2 or 3, X is halogen, and M is ammonium or alkali metal.
Abstract: Disclosed is an improved method for preparing 2,6-naphthalene dicarboxylic acid from di-lower alkyl 2,6-naphthalene dicarboxylate, which is characterized in that hydrolyzing di-lower alkyl 2,6-naphthalene dicarboxylate in a specified amount of water in the presence of specified amount of hydrophobic organic solvent and an additive; that hydrolyzing di-lower alkyl 2,6-naphthalene dicarboxylate in a specific amount of a mixed solvent of non-water miscible alcohol and water; or in that di-lower alkyl 2,6-naphthalene dicarboxylate is hydrolyzed in two steps wherein the 1st step comprises hydrolyzing said ester in a water miscible organic solvent in the presence of a small amount of water, and the 2nd step comprises further hydrolyzing the reaction.
Abstract: The compound represented by the following formula (1): wherein A, B, R1, R2, R3 and Z are as defined in the specification is analogous to shogaol and gingerol useful in the fields of foods, medicines, quasi-drugs, cosmetics, etc., and more highly active in tyrosinase activity inhibition, etc. than shogaol and gingerol.
Abstract: Various 13C and 14C carbon labeled compounds Rf—bCF(U)y(T)zFormula 1A or Rf—bCF2bCF(U)y(T)zFormula 1B wherein Rf is a linear or branched perfluoroalkyl radical Z(CmF2m)—, m is 1, 3 to 20, or a mixture thereof; Z is F when m is 1, and Z is F, Cl, or H when m is 3 to 20 or a mixture thereof; b is 13 or 14; y is 1, and z is 0 or 1; and when y and z are each 1, U is F, and T is selected from the group consisting of monovalent radicals —X wherein X is I or Br, —CH2—CH2—X, —CH?CH2, —CH2—CH2—OH, —CH2—COOH, —CH2OH, —bCH2OH, —COOH, —bCOOH, —O—CF(CF3)—C(O)F, —O—CF(CF3)—X, —SO2Y wherein Y is H, F or Cl, and —SO3H; and when y is 1, and z is 0, U is selected from the group consisting of divalent radicals ?CH—COOH, ?CH—CH2—OH, and ?O, are disclosed, and a process for their preparation which selectively introduces 13C and 14C carbon labels into a fluoroalkyl chain.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
April 1, 2008
Assignee:
E.I. du Pont de Nemours and Company
Inventors:
Alexander Borisovich Shtarov, Jon Lee Howell
Abstract: The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.
Type:
Grant
Filed:
June 3, 2005
Date of Patent:
April 1, 2008
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Xiaoli Chen, Keith T. Demarest, Jung Lee, Jay M. Matthews, Philip Rybczynski
Abstract: The present invention relates a composition having a high content of xanthophyll esters, where the xanthophyll ester component of the composition is comprised of a high proportion of trans-lutein esters. The present invention also provides methods of making and using such a composition.
Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.
Abstract: A method for the production of 6,6,6-trihalo-3,5-dioxohexanoic acid esters of formula (I): in addition to the enols thereof and <I>E</I> and <I>Z</I> isomers, wherein X independently represents fluorine, chlorine or bromine and R1 represents alkyl, cycloalkyl, aryl or aralkyl. A method for the production of enol ethers of formula (Ib): and the enols thereof (E and Z isomers) wherein X and R1 have the above-mentioned meanings.
Abstract: The present invention is directed to a process for preparing Mannich condensation product sequestering agents or mixtures of Mannich condensation product sequestering agents for use in fuels and lubricating oils.
Abstract: A method for the production of 6,6,6-trihalo-3,5-dioxhexanoic acid esters of formula (I): in addition to the enols thereof and <I>E</I> and <I>Z</I> isomers, wherein X independently represents fluorine, chlorine or bromine and R1 represents alkyl, cycloalkyl, aryl or aralkyl. A method for the production of enol ethers of formula (Ib): and the enols thereof (E and Z isomers) wherein X and R1 have the above-mentioned meanings.
Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.
Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
March 25, 2008
Assignee:
Merck & Co., Inc.
Inventors:
Philippe G. Nantermet, Hemaka Anthony Rajapakse, Harold G. Selnick
Abstract: A tetraalkylphosphonium salt having at least one branched alkyl chain containing 9 to 100 carbon atoms in total, an organically modified layered silicate containing the tetraalkylphosphonium salt having at least one branched alkyl chain containing 9 to 100 carbon atoms in total between layers of a layered silicate and a composition comprising the organically modified layered silicate and an organic solvent or a thermoplastic resin. There are provided a tetraalkylphosphonium salt for a layered silicate having thermal stability and dispersibility superior to those of conventional organophilized layered silicates, an organically modified layered silicate containing the tetraalkylphosphonium salt and a composition thereof.